China Pharma Holdings, Inc. Announces First Quarter 2007 Results

2007-05-15 20:04 937

HAIKOU CITY, Hainan Province, China, May 15 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. (“China Pharma”) (OTC Bulletin Board: CPHI), a specialty bio-pharmaceutical company that develops, manufactures and markets Western and Chinese medicines, today announced its financial results for the first quarter 2007 ended March 31, 2007.

First Quarter 2007 Highlights

-- Revenue increased 52.8% year-over-year to $7.2 million

-- Newly introduced hepatocyte growth promoting factor and ozagrel sodium

represented 8.5% and 10.7% of revenue, respectively

-- Net income was $2.4 million, up 46.6% year-over-year

China Pharma’s revenue in the first quarter of 2007 was $7.2 million, up 52.8% year-over-year from $4.7 million. The revenue increase for the quarter is attributed to a larger number of therapeutics on the market and increased market penetration. Gross profit increased 49.5% to $3.3 million from $2.2 million in the first quarter of 2006. Net income was $2.4 million, up 46.6% from $1.6 million in the same period a year ago. Results in the first quarter of 2007 benefited from net proceeds of $0.7 million from the sale of two pharmaceutical formulas. Fully diluted earnings per share were $0.07 compared to $0.05 in the first quarter 2006.

“We are happy to report another quarter of increasing revenue and net income growth. Our increased market penetration for our existing portfolio combined with the wide acceptance of our newly introduced therapeutics hepatocyte growth promoting factor and ozagrel sodium contributed to our strong revenue growth,” commented Ms. Zhi-lin Li, President and CEO of China Pharma.

Revenue growth for the quarter was led by growth in sales of gastrodin, which increased over 200%, and cefaclor, which increased over 100% from the first quarter of 2006. Sales of newly launched hepatocyte growth factor and ozagrel remained strong, contributing to 8.5% and 10.0% of revenue, respectively. No single therapeutic accounted for more than 15% of revenue during the quarter.

Gross profit for the first quarter of 2007 was $3.3 million, up 49.5% from $2.2 million in the first quarter of 2006. Gross margin was 45.6% compared to 46.6% from the same period a year ago. The slight variation in gross margin is attributed to product mix.

Selling expenses were $0.1 million for the quarter, or 2.0% of revenue, compared to $0.1 million, or 1.9% of revenue, in the same quarter last year. The slight increase in selling expenses was due to the increase in overall sales.

General and administrative (G&A) expenses were $1.4 million, or 19.1% of revenue, in the first quarter of 2007 compared to $0.3 million, or 5.6% of revenue, in the same period a year ago. G&A expense includes a $1.0 million write off of bad debt in during the quarter. Because the pharmaceutical industry in China typically has long collection cycles, the company writes off 50% of any receivables outstanding for more than twelve months. In the past, China Pharma has recovered outstanding long-term receivables.

The company recognized $0.8 million in research and development (“R&D”) expense during the quarter. The R&D expense represents costs associated with the sale of technological formulas during the quarter.

Income from operations was $0.9 million compared to $1.9 million in the first quarter of 2006.

During the quarter, China Pharma received $1.5 million in other income associated with the sale of technological formulas in the research and development stage. The company periodically sells certain technological formulas it determines will provide a higher return on investment in lieu of fully developing and launching these drugs in the market.

Net income for the first quarter of 2007 was $2.4 million, up 46.6% from $1.6 million in the first quarter of 2006. Fully diluted earnings per share were $0.07 compared to fully diluted earnings per share of $0.05. Fully diluted shares outstanding in the first quarter of 2007 were 36.3 million compared to 34.7 million in the comparable period a year ago.

Financial Condition

As of March 31, 2007, China Pharma had $3.0 million in cash and cash equivalents, total liabilities of $8.1 million and working capital of $24.5 million. Days sales outstanding were 174 days. Shareholders’ equity stood at $27.2 million compared to $20.9 million as of December 31, 2006.

Business Outlook

China Pharma has developed a diversified portfolio of therapeutics that, in aggregate, has contributed to revenue growth as the company expands its market penetration. It has already received approval for granisetron hydrochloride which it plans to launch in the second half of 2007. Moreover, the company is benefiting from the People’s Republic of China’s (PRC) commitment of $1.3 billion this year to expand its rural cooperative medical system to cover the entire country by 2010. China Pharma is reaffirming its full year guidance for 2007 of 30% increase in net income over 2006.

“We have developed a strong position in the pharmaceutical industry in China which supports our continued growth in both revenues and net income. The Chinese government is implementing some important changes which will benefit China Pharma, namely the new rural cooperative medical-care system and longer-term the State Food and Drug Administration’s tighter controls on the oversight of the drug approval process,” commented Ms. Li. “We feel both of these changes are positive for the industry and will enhance our competitive position.”

Conference Call

China Pharma will host a conference call on Tuesday, May 15 at 10:00 am EDT to discuss first quarter 2007 results. To participate in the conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (888) 481-7939. International callers should dial (617) 847-8707. The conference passcode is 845 135 91.

If you are unable to participate in the call at this time, a replay will be available on May 15th at 12:00 pm EDT, through May 22nd. To access the replay, dial (888) 286-8010. International callers should dial (617) 801-6888. The conference passcode is 71744541.

The conference will be broadcast live over the Internet and can be accessed by all interested parties at China Pharma’s website at . To listen to the call please go to the website at least 15 minutes prior to the start of the call to register, download and install any necessary audio software.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, vascular, CNS and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty bio-pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. For more information on the Company go to .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company’s filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company’s expectations.





For the three months

ended March 31,

2007 2006

Revenue $7,233,768 $4,732,991

Cost of revenue 3,934,849 2,526,020

Gross profit 3,298,919 2,206,971

Operating expenses:

Selling expenses 147,883 88,030

General and administrative 1,380,076 264,200

Research and development 836,404 --

Total operating expenses 2,364,363 352,230

Income from operations 934,556 1,854,741

Non-operating income (expenses):

Interest income 13,775 147

Interest expense (56,899) (23,799)

Other income 1,482,607 22,636

Total non-operating income (expense) 1,439,483 (1,016)

Income before taxes 2,374,039 1,853,725

Income tax expense -- (234,789)

Net income $2,374,039 $1,618,936

Comprehensive income - foreign currency

translation adjustments 216,416 59,085

Comprehensive income $2,590,455 $1,678,021

Basic and diluted earnings per common

share $0.07 $0.05

Weighted-average common shares

outstanding 36,337,958 34,723,056




March 31, December 31,

2007 2006


Current Assets:

Cash and cash equivalents $2,950,719 $656,441

Trade accounts receivable, less allowance

for doubtful of $2,603,164 and

$1,562,494, respectively 13,956,681 12,101,979

Other receivables, less allowance for

doubtful accounts of $29,244 and

$27,517, respectively 1,634,790 355,554

Deferred offering costs -- 59,390

Advances to suppliers 2,538,017 2,255,877

Inventory 11,476,631 10,277,887

Total Current Assets 32,556,838 25,707,128

Non-current Assets:

Property and equipment, net of accumulated

depreciation of $713,323 and $619,649,

respectively 2,660,818 2,725,173

Intangible assets, net of accumulated

amortization of 192,778 and

$184,175, respectively 59,208 65,344

Deferred tax assets 16,901 16,736

Total Non-current Assets 2,736,927 2,807,253

TOTAL ASSETS $35,293,765 $28,514,381


Current Liabilities:

Trade accounts payable $735,664 $477,291

Accrued expenses 133,317 104,216

Accrued taxes payable 248,139 167,419

Other payables 112,828 185,096

Advances from customers 149,870 141,871

Accounts payable -related parties 45,544 22,650

Short-term notes payable 6,598,260 6,533,649

Total Current Liabilities 8,023,622 7,632,192

Research and development commitments 32,296 31,980

Total Liabilities 8,055,918 7,664,172

Stockholders’ Equity:

Common stock, $0.001 par value, 60,000,000

shares authorized, 37,228,938 and

34,723,056 shares issued and outstanding,

respectively 37,229 34,723

Additional paid-in capital 11,559,656 7,764,979

Foreign currency translation adjustment 880,287 663,871

Retained earnings 14,760,675 12,386,636

Total Stockholders’ Equity 27,237,847 20,850,209





For the three For the three

months ended months ended

March 31, March 31,

2007 2006

Cash Flows from Operating Activities:

Net income $2,374,039 $1,618,936

Depreciation and amortization 100,063 85,140

Changes in assets and liabilities:

Trade accounts receivable (1,728,236) (2,541,404)

Other receivables (1,309,181) (296,864)

Advances to suppliers (258,815) 401,068

Inventory (1,092,813) (765,072)

Deferred tax assets -- (25,892)

Deferred offering costs 59,743 --

Trade accounts payable 247,713 728,040

Accrued expenses 27,960 16,465

Accrued taxes payable 78,756 372,256

Other payables 88,814 (44,269)

Advances from customers 6,571 (264)

Net Cash Used in Operating Activities (1,405,386) (451,860)

Cash Flows from Investing Activities:

Purchase of property and equipment (2,360) (22,074)

Sale of technology 38,453 --

Purchase of intangible assets -- (2,472)

Net Cash (Used) by Investing

Activities 36,093 (24,546)

Cash Flows from Financing Activities:

Proceeds from sale of common stock

and warrants 3,797,183 --

Related party payables/receivables (138,860) --

-- --

Net Cash Proceeds from Financing

Activities 3,658,323 --

Effect of Exchange Rate Changes on

Cash 5,247 90,110

Net Change in Cash 2,294,277 (386,296)

Cash and Cash Equivalents at

Beginning of Period 656,441 461,220

Cash and Cash Equivalents at End of

Period $2,950,718 $74,924

For more information, please contact:

Crocker Coulson, President, or

Leslie Richardson, Financial Writer

CCG Elite

Tel: +1-310-231-8600 x103


Source: China Pharma Holdings, Inc.
Related Stocks: